• Change and percent change from baseline to the surgery of treatment for LDL-C, HDL-C, TC, and TG for subjects [ Time Frame: within 24h before surgery ] [ Designated as safety issue: Yes ]
• Change and percent change from baseline to the surgery of treatment for hs-CRP [ Time Frame: within 24h before surgery ] [ Designated as safety issue: Yes ]
• Safety of atorvastatin through laboratory assessment [ Time Frame: within 24h before surgery ] [ Designated as safety issue: Yes ]

This study is designed to determine if the use of atorvastatin (Lipitor), a member of the HMG coA reductase inhibitor class of drugs referred to as statins, will reduce cardiovascular outcomes ( mortality - myocardial infarction - stroke ) when given in high doses in comparative standard doses in the perioperative period of major vascular surgery.

Abdominal aortic aneurysm , Carotid endarterectomy , Revascularization of lower limbs

• Active Comparator: Use Atorvastatin 80mg for 60 days , and the vascular surgery will be made between day-7 and day-60
• Active Comparator: Use Atorvastatin 20 mg for 60 days , and the vascular surgery will be made between day-7 and day-60

Inclusion Criteria:

• Vascular surgery (abdominal aortic aneurysm , carotid endarterectomy , limbs revascularization)

Exclusion Criteria:

• Pregnant or lactating women
• Patient with sensitivity to atorvastatin
• Patient has elevations in certain laboratory values (CK, AST, ALT)
• Known history of active hepatic disease or known hepatic insufficiency
• Patients participating in another clinical trial
• Prior statin therapy to include: >10 mg of atorvastatin (Lipitor) or >20 mg of other HMG-CoA Reductase Inhibitors (statins) or use rosuvastatin
• Serious infectious disease after surgery
• Known history of cancer